Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeqi Huang

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 27, 2011
Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonistsMing Tao, Lisa D Aimone, John A Gruner, et al.
Journal of Translational Medicine|December 4, 2024
Cellular crosstalk in the bone marrow nicheZeqi Huang, Zoya Iqbal, Zhe Zhao, et al.
Scientific Reports|July 8, 2026
Comparative repair efficacy of three mesenchymal stem cell sources in rat full-thickness talar cartilage defectsZeqi Huang, Bin Jiang, Chunyan Yang, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2011
4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonistsRobert L Hudkins, Lisa D Aimone, Reddeppa Reddy Dandu, et al.
Bioorganic & Medicinal Chemistry Letters|February 1, 2012
4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activityRobert L Hudkins, Allison L Zulli, Reddeppa reddy Dandu, et al.
Chemical Research in Toxicology|October 26, 2011
2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formationKevin J Wells-Knecht, Gregory R Ott, Mangeng Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2011
2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formationLinda R Weinberg, Mark S Albom, Thelma S Angeles, et al.
Bioorganic & Medicinal Chemistry Letters|February 7, 2015
Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinaseEugen F Mesaros, Thelma S Angeles, Mark S Albom, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.
Journal of Medicinal Chemistry|August 24, 2011
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activityGregory R Ott, Gregory J Wells, Tho V Thieu, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|December 27, 2011
Synthesis and structure-activity relationship of 5-pyridazin-3-one phenoxypiperidines as potent, selective histamine H(3) receptor inverse agonistsMing Tao, Lisa D Aimone, John A Gruner, et al.
Journal of Translational Medicine|December 4, 2024
Cellular crosstalk in the bone marrow nicheZeqi Huang, Zoya Iqbal, Zhe Zhao, et al.
Scientific Reports|July 8, 2026
Comparative repair efficacy of three mesenchymal stem cell sources in rat full-thickness talar cartilage defectsZeqi Huang, Bin Jiang, Chunyan Yang, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2011
4,5-dihydropyridazin-3-one derivatives as histamine H₃ receptor inverse agonistsRobert L Hudkins, Lisa D Aimone, Reddeppa Reddy Dandu, et al.
Bioorganic & Medicinal Chemistry Letters|February 1, 2012
4-phenoxypiperidine pyridazin-3-one histamine H(3) receptor inverse agonists demonstrating potent and robust wake promoting activityRobert L Hudkins, Allison L Zulli, Reddeppa reddy Dandu, et al.
Chemical Research in Toxicology|October 26, 2011
2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formationKevin J Wells-Knecht, Gregory R Ott, Mangeng Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2011
2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formationLinda R Weinberg, Mark S Albom, Thelma S Angeles, et al.
Bioorganic & Medicinal Chemistry Letters|February 7, 2015
Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinaseEugen F Mesaros, Thelma S Angeles, Mark S Albom, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.
Journal of Medicinal Chemistry|August 24, 2011
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activityGregory R Ott, Gregory J Wells, Tho V Thieu, et al.
Pageof 4